N
Nils G. Morgenthaler
Researcher at Charité
Publications - 237
Citations - 16810
Nils G. Morgenthaler is an academic researcher from Charité. The author has contributed to research in topics: Copeptin & Natriuretic peptide. The author has an hindex of 69, co-authored 234 publications receiving 15477 citations. Previous affiliations of Nils G. Morgenthaler include Thermo Fisher Scientific.
Papers
More filters
Journal ArticleDOI
Assay for the Measurement of Copeptin, a Stable Peptide Derived from the Precursor of Vasopressin
TL;DR: Copeptin is stable for days after blood withdrawal and can be quickly and easily measured, and may be a useful alternative to direct measurement of AVP concentration.
Journal ArticleDOI
Novel and Conventional Biomarkers for Prediction of Incident Cardiovascular Events in the Community
Olle Melander,Christopher Newton-Cheh,Christopher Newton-Cheh,Peter Almgren,Bo Hedblad,Göran Berglund,Gunnar Engström,Margaretha Persson,J. Gustav Smith,Martin Magnusson,Anders Christensson,Joachim Struck,Nils G. Morgenthaler,Andreas Bergmann,Michael J. Pencina,Thomas J. Wang +15 more
TL;DR: Evaluated biomarkers may be used to predict future cardiovascular events, but the gains over conventional risk factors are minimal and greater improvements were observed in analyses restricted to intermediate-risk individuals.
Journal ArticleDOI
Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea : results from the BACH (Biomarkers in Acute Heart Failure) trial
Alan S. Maisel,Christian Mueller,Richard M. Nowak,W. Frank Peacock,Judd W. Landsberg,Piotr Ponikowski,Martin Möckel,Christopher Hogan,Alan H.B. Wu,Mark Richards,Paul Clopton,Gerasimos Filippatos,Salvatore Di Somma,Inder S. Anand,Leong L. Ng,Lori B. Daniels,Sean-Xavier Neath,Robert H. Christenson,Mihael Potocki,James McCord,Garret Terracciano,Dimitrios Th. Kremastinos,Oliver Hartmann,Stephan von Haehling,Andreas Bergmann,Nils G. Morgenthaler,Stefan D. Anker +26 more
TL;DR: MR-proANP is as useful as BNP for AHF diagnosis in dyspneic patients and may provide additional clinical utility when BNP is difficult to interpret, and MR-proADM identifies patients with high 90-day mortality risk and adds prognostic value to BNP.
Journal ArticleDOI
Incremental Value of Copeptin for Rapid Rule Out of Acute Myocardial Infarction
Tobias Reichlin,Willibald Hochholzer,Claudia Stelzig,Kirsten Laule,Heike Freidank,Nils G. Morgenthaler,Andreas Bergmann,Mihael Potocki,Markus Noveanu,Tobias Breidthardt,Andreas Christ,Tujana Boldanova,Ramona Merki,Nora Schaub,Roland Bingisser,Michael Christ,Christian Mueller +16 more
TL;DR: The additional use of copeptin seems to allow a rapid and reliable rule out of AMI already at presentation and may thereby obviate the need for prolonged monitoring and serial blood sampling in the majority of patients.
Journal ArticleDOI
Thyrotropin Receptor Autoantibodies Are Independent Risk Factors for Graves’ Ophthalmopathy and Help to Predict Severity and Outcome of the Disease
Anja Eckstein,Marco Plicht,Hildegard Lax,Markus Neuhäuser,Klaus Mann,Sebastian Lederbogen,Christian Heckmann,Joachim Esser,Nils G. Morgenthaler +8 more
TL;DR: Follow-up measurements of TBII allow, in half of the patients, assessment of the prognosis of GO and, therefore, could be of additional help for the disease management.